An update on the immune landscape in lung and head and neck cancers.
hypopharyngeal neoplasms
laryngeal neoplasms
lung neoplasms
medical oncology
Journal
CA: a cancer journal for clinicians
ISSN: 1542-4863
Titre abrégé: CA Cancer J Clin
Pays: United States
ID NLM: 0370647
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
31
03
2020
revised:
03
06
2020
accepted:
04
06
2020
pubmed:
26
8
2020
medline:
21
5
2021
entrez:
26
8
2020
Statut:
ppublish
Résumé
Immunotherapy has dramatically changed the treatment landscape for patients with cancer. Programmed death-ligand 1/programmed death-1 checkpoint inhibitors have been in the forefront of this clinical revolution. Currently, there are 6 US Food and Drug Administration-approved checkpoint inhibitors for approximately 18 different histologic types of cancer. Lung cancer and head and neck squamous cell carcinoma (HNSCC) are 2 diseases that have led the way in the development of immunotherapy. Atezolizumab, durvalumab, nivolumab, and pembrolizumab are all currently used as part of standard-of-care treatment for different stages of lung cancer. Similarly, nivolumab and pembrolizumab have US regulatory approval as treatment for advanced metastatic HNSCC. This is significant because lung cancer represents the most common and most fatal cancer globally, and HNSCC is the sixth most common. Currently, most of the approvals for the use of immunotherapy agents are for patients diagnosed in the metastatic setting. However, research is ongoing to evaluate these drugs in earlier stage disease. There is plausible biological rationale to expect that pharmacologic activation of the immune system will be effective for early-stage and smaller tumors. In addition, selecting patients who are more likely to respond to immunotherapy and understanding why resistance develops are crucial areas of ongoing research. The objective of this review was to provide an overview of the current immune landscape and future directions in lung cancer and HNSCC.
Substances chimiques
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-517Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 American Cancer Society.
Références
WeiSC, DuffyCR, AllisonJP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov.2018;8:1069-1086.
PostowMA, SidlowR, HellmannMD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med.2018;378:158-168.
RizviNA, HellmannMD, SnyderA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science.2015;348:124-128.
SiuLL, EvenC, MesiaR, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial. JAMA Oncol.2019;5:195-203.
BorghaeiH, Paz-AresL, HornL, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med.2015;373:1627-1639.
BrahmerJ, ReckampKL, BaasP, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med.2015;373:123-135.
HerbstRS, BaasP, KimDW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet.2016;387:1540-1550.
RittmeyerA, BarlesiF, WaterkampD, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet.2017;389:255-265.
BorcomanE, NandikollaA, LongG, GoelS, Le TourneauC. Patterns of response and progression to immunotherapy. Am Soc Clin Oncol Educ Book.2018;38:169-178.
BrahmerJR, LacchettiC, SchneiderBJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol.2018;36:1714-1768.
GaronEB, RizviNA, HuiR, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med.2015;372:2018-2028.
ReckM, Rodriguez-AbreuD, RobinsonAG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med.2016;375:1823-1833.
ReckM, Rodriguez-AbreuD, RobinsonAG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol.2019;37:537-546.
GaronEB, HellmannMD, RizviNA, et al. Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol.2019;37:2518-2527.
MokTSK, WuYL, KudabaI, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet.2019;393:1819-1830.
GandhiL, Rodriguez-AbreuD, GadgeelS, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med.2018;378:2078-2092.
SocinskiMA, JotteRM, CappuzzoF, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med.2018;378:2288-2301.
SchoenfeldAJ, ArbourKC, RizviH, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol.2019;30:839-844.
YangJC, ShepherdFA, KimDW, et al. Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report. J Thorac Oncol.2019;14:933-939.
AhnM, HanJ, SequistL, et al. OA 09.03 TATTON ph Ib expansion cohort: osimertinib plus savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI [abstract]. J Thorac Oncol. 2017;12(suppl 2):S1768.
LisbergA, CummingsA, GoldmanJW, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol.2018;13:1138-1145.
National Comprehensive Cancer Network. NCCN Guidelines, Version 3.2020: Non-Small Cell Lung Cancer. National Comprehensive Cancer Network; 2020.
Paz-AresL, LuftA, VicenteD, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med.2018;379:2040-2051.
HellmannMD, Paz-AresL, Bernabe CaroR, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med.2019;381:2020-2031.
MunhozRR, PostowMA. Clinical development of PD-1 in advanced melanoma. Cancer J.2018;24:7-14.
MotzerRJ, RiniBI, McDermottDF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol.2019;20:1370-1385.
HellmannMD, CiuleanuTE, PluzanskiA, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med.2018;378:2093-2104.
AuperinA, Le PechouxC, RollandE, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol.2010;28:2181-2190.
AntoniaSJ, VillegasA, DanielD, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med.2017;377:1919-1929.
AntoniaSJ, VillegasA, DanielD, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med.2018;379:2342-2350.
GrayJE, VillegasA, DanielD, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol.2020;15:288-293.
PignonJP, TribodetH, ScagliottiGV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol.2008;26:3552-3559.
GoldstrawP, ChanskyK, CrowleyJ, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer. J Thorac Oncol.2016;11:39-51.
OwenD, ChaftJE. Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis.2018;10(suppl 3):S404-S411.
FordePM, ChaftJE, SmithKN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med.2018;378:1976-1986.
HellmannMD, ChaftJE, WilliamWNJr, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol.2014;15:e42-e50.
RuschVW, ChaftJE, JohnsonB, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): initial results from a multicenter study (LCMC3) [abstract]. J Clin Oncol.2018;36(15 suppl):8541.
CasconeT, WilliamWN, WeissferdtA, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical and correlative results from the NEOSTAR study [abstract]. J Clin Oncol.2019;37(15 suppl):8504.
ProvencioM, NadalE, InsaA, et al. Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): a phase II multicenter exploratory study-final data of patients who underwent surgical assessment [abstract]. J Clin Oncol.2019;37:8509.
WuYL, HerbstRS, MannH, RukazenkovY, MarottiM, TsuboiM. ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer.2018;19:e533-e536.
CarlisleJW, RamalingamSS. Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncol.2019;15:805-816.
SolomonBJ, AhnJS, BarlesiF, et al. ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2019;37(15 suppl):TPS8569.
HornL, MansfieldAS, SzczesnaA, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med.2018;379:2220-2229.
Paz-AresL, DvorkinM, ChenY, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet.2019;394:1929-1939.
TurrisiAT3rd, KimK, BlumR, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med.1999;340:265-271.
HannCL, ScherpereelA, HellyerJA, WakeleeHA. Role of immunotherapy in small cell lung cancer, thymic epithelial tumors, and mesothelioma. Am Soc Clin Oncol Educ Book.2019;39:543-552.
AntoniaSJ, Lopez-MartinJA, BendellJ, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol.2016;17:883-895.
ReckM, VicenteD, CiuleanuT, et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331. Ann Oncol. 2018;29(suppl 10):mdy511-0004.
OttPA, ElezE, HiretS, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol.2017;35:3823-3829.
ChungHC, Lopez-MartinJA, KaoSCH, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158 [abstract]. J Clin Oncol.2018;36(15 suppl):8506.
MehraR, SeiwertTY, GuptaS, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer.2018;119:153-159.
SeiwertTY, BurtnessB, MehraR, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol.2016;17:956-965.
LarkinsE, BlumenthalGM, YuanW, et al. FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist.2017;22:873-878.
BaumlJ, SeiwertTY, PfisterDG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol.2017;35:1542-1549.
VermorkenJB, TrigoJ, HittR, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol.2007;25:2171-2177.
FerrisRL, BlumenscheinGJr, FayetteJ, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med.2016;375:1856-1867.
FerrisRL, LicitraL, FayetteJ, et al. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use. Clin Cancer Res.2019;25:5221-5230.
SabaNF, BlumenscheinGJr, GuigayJ, et al. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by age. Oral Oncol.2019;96:7-14.
CohenEEW, SoulieresD, Le TourneauC, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet.2019;393:156-167.
LicitraLF, HaddadRI, EvenC, et al. EAGLE: a phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) [abstract]. J Clin Oncol.2019;37(15 suppl):6012.
VermorkenJB, MesiaR, RiveraF, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med.2008;359:1116-1127.
BurtnessB, HarringtonKJ, GreilR, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet.2019;394:1915-1928.
MillerDL, PuricelliMD, StackMS. Virology and molecular pathogenesis of HPV (human papillomavirus)-associated oropharyngeal squamous cell carcinoma. Biochem J.2012;443:339-353.
AngKK, HarrisJ, WheelerR, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med.2010;363:24-35.
PatelJJ, LevyDA, NguyenSA, KnochelmannHM, DayTA. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-systematic review and meta-analysis. Head Neck.2020;42:774-786.
KaramSD, RabenD. Radioimmunotherapy for the treatment of head and neck cancer. Lancet Oncol.2019;20:e404-e416.
FerrisRL, GillisonML, HarrisJ, et al. Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504 [abstract]a. J Clin Oncol.2018;36(15 suppl):6010.
GillisonML, TrottiAM, HarrisJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet.2019;393:40-50.
MehannaH, RobinsonM, HartleyA, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet.2019;393:51-60.
PalackdharryS, GillisonM, WordenF, et al. Neoadjuvant pembrolizumab is active in surgically resected head and neck cancer. Int J Radiat Oncol Biol Phys.2018;100:1365.
AggarwalC, CohenRB, MorrowMP, et al. Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer. Clin Cancer Res.2019;25:110-124.
CorralesL, DesbienAL, GauthierKES, et al. Abstract 1202: tumor cell intrinsic STING signaling demonstrates minimal contribution to the anti-tumor response elicited by the STING agonist ADU-S100 (MIW815). Cancer Res.2019;79(13 suppl):1202.
TaylorMH, RascoDW, BroseMS, et al. A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol.2018;36(15 suppl):6016.
SharmaP, Hu-LieskovanS, WargoJA, RibasA. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell.2017;168:707-723.
Mino-KenudsonM. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?Cancer Biol Med.2016;13:157-170.
McLaughlinJ, HanG, SchalperKA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol.2016;2:46-54.
HongL, DibajS, NegraoMV, et al. Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol.2019;37(15 suppl):9017.
ChanTA, YarchoanM, JaffeeE, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol.2019;30:44-56.
SnyderA, MakarovV, MerghoubT, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med.2014;371:2189-2199.
LeDT, UramJN, WangH, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med.2015;372:2509-2520.
RidkerPM, MacFadyenJG, ThurenT, et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet.2017;390:1833-1842.